VSTM Stock Recent News

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the.

Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment of LGSOC. The market was impressed with the data and VSTM is trading up over 100% from a month ago. It appears as if the market might have regained some conviction in Avutometinib and its ability to work in KRAS mutant and other cancers.

Trading penny stocks can be an exhilarating venture, offering the potential for significant returns. These low-cost shares, often priced under $5, represent a unique opportunity to participate in the growth of emerging companies, particularly in the dynamic tech sector.

The tech sector, a perpetually booming industry, presents an ocean of opportunities for investors, particularly those interested in trading penny stocks. These are low-priced stocks, typically trading for less than five dollars a share, representing smaller companies, including startups and those navigating through periods of financial recovery.

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30 p.m. ET. A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com.

With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy of their attention but often disregarding those obtainable for less than a dollar.

Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.